Safety and Biodistribution of Topical Laquinimod, an Immunomodulator Targeting Aryl Hydrocarbon Receptor: The LION Study
To evaluate the safety, tolerability, and distribution of laquinimod (LAQ) eye drops as a potential steroid-sparing anti-inflammatory therapy.
Authors
- Negin Yavari (ORCID: https://orcid.org/0000-0002-9914-2935)
- Muhammad Sohail Halim (ORCID: https://orcid.org/0000-0003-3208-7078)
- Yasser Serag (ORCID: https://orcid.org/0000-0002-6953-7012)
- Erik Vahtola
- Marie Törngren (ORCID: https://orcid.org/0000-0001-6693-0655)
- Christopher Or
- Anh N.T. Tran (ORCID: https://orcid.org/0000-0002-8819-3876)
- Hareem U Khan
- Ngoc Trong Tuong Than (ORCID: https://orcid.org/0000-0002-6123-675X)
- Arto Urtti (ORCID: https://orcid.org/0000-0001-6064-3102)
- Azadeh Mobasserian
- Anadi Khatri (ORCID: https://orcid.org/0000-0002-0444-224X)
- Gunay Uludag Kirimli
- Quan Dong Nguyen (ORCID: https://orcid.org/0000-0002-6024-8441)
- Osama Elaraby (ORCID: https://orcid.org/0009-0004-2907-0050)
- Dalia El Feky
- Mamdouh Mahmoud Kabeel
- SD Smith
- Charles DeBoer
- Jia-Horung Hung
- Diano V. Do
- Magdy Moussa
- Amir Akhavanrezayat
- Prithvi Mruthyunjaya
Institutions
- University of Eastern Finland (FI)
- Tanta University (EG)
- Active Biotech (Sweden) (SE)
- Lumbini Eye Institute (NP)
- Kathmandu University (NP)
- Smith-Kettlewell Eye Research Institute (US)
- Stanford University (US)
Publication Details
- Journal
- Ophthalmology Science
- Published
- 2026-04-01
- DOI
- https://doi.org/10.1016/j.xops.2026.101186
- Primary Topic
- Pediatric health and respiratory diseases
- Type
- article
- Field-Weighted Citation Impact
- 0.00